Skip to main content
Erschienen in: BMC Nephrology 1/2022

Open Access 01.12.2022 | Research

Factors associated with aortic valve stenosis in Japanese patients with end-stage kidney disease

verfasst von: Yuji Sasakawa, Naoki Okamoto, Maya Fujii, Jyoichiro Kato, Yukio Yuzawa, Daijo Inaguma

Erschienen in: BMC Nephrology | Ausgabe 1/2022

Abstract

Background

Aortic valve stenosis (AS) has a high prevalence and poor prognosis in patients who receive maintenance dialysis. However, few large-scale observational studies in Japan have investigated patients with AS who underwent dialysis. In this study, we investigated the prevalence and factors associated with AS in Japanese patients who underwent dialysis.

Methods

In this cross-sectional analysis, we enrolled patients who underwent dialysis and transthoracic echocardiography between July 1, 2017 and June 30, 2018. Patients with a maximum aortic jet velocity (Vmax) ≥ 2.0 m/s, pressure gradient (PG) between the left ventricle and ascending aorta (mean PG) ≥ 20 mmHg, or aortic valve area (AVA) ≤ 1.0 cm2 were categorized into the AS group (G1). Patients with Vmax ≥ 3.0 m/s, mean PG ≥ 20 mmHg, or AVA ≤ 1.0 cm2 were categorized into the moderate and severe AS groups (G2). We performed multivariate logistic regression analysis and compared G1 and G2 with the non-AS group to determine the risk factors for AS. We also investigated the risk factors for aortic valve calcification, which is a pre-stage for AS.

Results

Of the 2,786 patients investigated, 555 (20.0%) and 193 (6.9%) were categorized into G1 and G2, respectively. Multivariate logistic regression analysis revealed that age, long-term dialysis, and elevated serum phosphorus levels were associated with AS in both the groups (p < 0.05). These factors were converted into ordinal categories, and a multivariate logistic regression analysis was performed. Patients with serum phosphorus levels measuring 5.0–5.9 mg/dL and > 6.0 mg/dL showed a higher risk of AS than those with serum phosphorus levels measuring < 4.0 mg/dL (odds ratio 2.24, p = 0.01 and odds ratio 2.66, p = 0.005, respectively). Aortic valve calcification was associated with age, long-term dialysis, diabetes mellitus, administration of vitamin D receptor activators, elevated serum calcium levels, and anemia (p < 0.05 for all).

Conclusions

Patients on dialysis showed a high prevalence of AS, which was associated with age, long-term dialysis, and elevated serum phosphorus levels.

Trial registration

UMIN000026756, registered on March 29, 2017.
Begleitmaterial
Hinweise

Supplementary Information

The online version contains supplementary material available at https://​doi.​org/​10.​1186/​s12882-022-02758-y.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
CKD
Chronic kidney disease
CVD
Cardiovascular disease
AS
Aortic valve stenosis
AVA
Aortic valve area
MBD
Mineral and Bone Disorder
TTE
Transthoracic echocardiography
PG
Pressure gradient
Vmax
Maximum aortic jet velocity
MOR
Multivariate-adjusted odds ratio
CI
Confidence interval
VDRA
Vitamin D receptor activators

Background

Chronic kidney disease (CKD) is a significant risk factor for cardiovascular disease (CVD) [15]. The prevalence of CVD, particularly aortic valve stenosis (AS), ranges from 13 to 25% in patients on dialysis, [6, 7] which is higher than the prevalence (2.3%–4.3%) in the general elderly population [8, 9]. Previous clinical studies have reported that AS in patients on dialysis is characterized by a rapid decrease in aortic valve area (AVA) and rapid progression of valve calcification [10, 11]. Additionally, survival rates are lower in AS patients with CKD than in those without [12, 13].
Age-induced changes in the aortic valve, leading to sclerosis and calcification, [14] have replaced rheumatic fever as the primary cause of AS [15]. Morphological changes secondary to mechanical stress, endothelial injury, inflammation, and valve hemorrhage [16] can lead to aortic valve leaflet thickening, fibrosis, and calcification, eventually causing stenosis. However, the mechanisms underlying these changes remain unclear. Regarding the risk factors, a few studies have reported that age, male sex, hypertension, dyslipidemia, and smoking are associated with valve degeneration [9, 17, 18]. Other studies have reported that hypertension, dyslipidemia, diabetes mellitus, and renal insufficiency are not associated with AS progression [1921].
The prevalence of hypertension, diabetes mellitus, and mineral and bone disorders (MBD) is higher in patients on dialysis compared to the general population. These conditions are associated with arteriosclerosis and CVD [2228]. The factors associated with AS in patients on dialysis have not been investigated by a large-scale cohort study. Therefore, we conducted a multicenter prospective cohort study to investigate the factors associated with AS, the prevalence, and prognosis of patients with AS who have had dialysis. In this study, only the results of the cross-sectional analysis of the included patients at baseline in the multicenter prospective cohort study were reported.

Materials and methods

Study population

The study included patients aged ≥ 20 years who underwent outpatient maintenance dialysis for > 1 year across 58 hospitals in the Tokai region of Japan. The baseline was selected as the time of transthoracic echocardiography (TTE) performed between July 1, 2017 and June 30, 2018. Patients with a history of aortic valve surgery and those who refused to participate in the study were excluded. 2,916 patients were enrolled and the following data was recorded: Patients’ background, history, comorbidities, medications, laboratory data, chest radiography findings, electrocardiogram tracings, and TTE images. Out of the 2,916 patients enrolled in the study, 130 patients who met the following criteria were excluded: duration of dialysis < 1 year, unknown initiation of dialysis, history of aortic valve surgery, or TTE performed outside the observation period.

Definition of aortic stenosis and aortic valve calcification

All the patients underwent a TTE to measure the parameters associated with AS and to evaluate for aortic valve calcification. The maximum aortic jet velocity (Vmax), pressure gradient (PG) between the left ventricle and ascending aorta (mean PG), and the AVA was recorded to evaluate for AS. Aortic stenosis was defined based on the 2014 American Heart Association/American College of Cardiology Guidelines for the Management of Patients with Valvular Heart Disease. It was defined as (a) Vmax ≥ 2.0 m/s, (b) mean PG ≥ 20 mmHg, or (c) AVA ≤ 1.0 cm2. Patients who met any of the criteria were categorized into the AS group (G1); the rest were categorized into the non-AS group. Among the patients in G1, the moderate and severe AS groups were categorized as G2, with the Vmax criterion changed from ≥ 2.0 m/s to ≥ 3.0 m/s without any change in the mean PG and AVA criteria. Fig. 1 shows the patient flowchart.

Statistical analysis

Baseline data is presented as means (standard deviation), medians (interquartile range), or percentages for categorical measures. Fisher's exact test for nominal variables and the Mann–Whitney U test for continuous variables was used to compare the baseline data between G1 and the non-AS group and between G2 and the non-AS group. Factors associated with AS on univariate analysis were subjected to multivariate logistic regression analysis along with the factors associated with MBD. The following 14 variables were subjected to multivariate logistic regression analysis: sex, age, duration of dialysis, nephrosclerosis as the primary contributor to CKD, diabetes mellitus as a comorbidity, calcimimetic use, vitamin D receptor activator (VDRA) administration, phosphate binder use, serum albumin level, serum corrected calcium level, serum phosphorus level, serum intact parathyroid hormone level, serum C-reactive protein level, and serum hemoglobin level. Multivariate logistic regression analysis was performed with these 14 variables, and age, dialysis duration, and serum phosphorus levels that showed significant differences were converted into ordinal categories. Patients were categorized on the basis of age into the following groups: < 60, 60–69, 70–79, and ≥ 80 years. Multivariate logistic regression analysis was performed on these age ordinal categories and 13 other factors. Similarly, Patients were categorized into the following groups on the basis of the duration of dialysis and serum phosphorus levels: < 5, 5–9, 10–14, and ≥ 5 years and < 4.0, 4.0–4.9, 5.0–5.9, and ≥ 6.0 mg/dL, respectively.
Patients were further categorized into those with and without aortic valve calcification (a pre-stage of AS), and a multivariate logistic regression analysis was performed. The Mann–Whitney U test was used to compare the Vmax, mean PG, and AVA between patients with and without aortic valve calcification.
All statistical analyses were performed using the R software (The R Foundation for Statistical Computing, Vienna, Austria). All values were two-sided, and p < 0.05 was considered statistically significant.
This study was performed in accordance with the Ethics of Clinical Research (The Helsinki Declaration) and was approved by the Fujita Health University Center for Clinical Trial and Research Support (approval numbers: HM16–373). All patients included in this study provided informed consent after the purpose of the study was explained to them. This study was registered in the Clinical Trial Registry (UMIN 000,026,756) on April 1, 2017.

Results

Baseline patient characteristics

In total, 2,786 patients were enrolled in the study; 555 patients (20.0%) were categorized into G1 and 2,231 (80.0%) into the non-AS group. Out of the 555 patients in G1, 514 (92.6%) showed Vmax ≥ 2.0 m/s, 107 (19.3%) showed mean PG ≥ 20 mmHg, and 102 (18.6%) showed AVA ≤ 1.0 cm2. Based on these findings, the moderate and severe AS groups were categorized as G2, with the Vmax criterion changed from ≥ 2.0 m/s to ≥ 3.0 m/s without any change in the mean PG and AVA criteria. Among patients in G1, 193 (6.9%) were categorized as G2. Out of the 193 patients, 98 (50.8%) showed Vmax ≥ 3.0 m/s, 107 (55.4%) showed mean PG ≥ 20 mmHg, and 102 (52.8%) showed AVA ≤ 1.0 cm2. Table 1 shows a comparison of the baseline characteristics between G1 and the non-AS group and between G2 and the non-AS group. The median ages of G1, G2, and the non-AS groups were 75, 77, and 68 years, respectively. The median hemodialysis durations in G1, G2, and the non-AS groups were 8.0, 7.4, and 6.2 years, respectively. The prevalence of diabetes mellitus in G1, G2, and the non-AS groups were 36.0%, 39.9%, and 46.0%, respectively. No significant differences were observed in the mean serum phosphorus and corrected serum calcium levels in the groups. According to the TTE results, the percentages of aortic valve calcification in G1 and G2 were 80.7% and 83.8%, respectively, which were higher than the percentage in the non-AS group (53.3%).
Table 1
Comparison of baseline characteristics between G1 and the non-AS group and between G2 and the non-AS group
 
non-AS group
G1
p value
G2
p value
Basic Characteristics
 Male, %
67.0
63.6
0.13
59.6
0.04
 Age, years
68 (59–75)
75 (68–82)
 < 0.001
77 (70–83)
 < 0.001
 Duration of dialysis, years
6.2 (3.1–12.4)
8.0 (3.8–15.1)
 < 0.001
7.4 (4.0–14.8)
0.005
Primary Disease
 Nephrosclerosis, %
11.9
17.3
0.001
16.6
0.07
 Diabetic nephropathy, %
39.8
29.5
 < 0.001
31.6
0.03
 Chronic glomerulonephritis, %
19.5
23.8
0.03
23.8
0.16
Comorbidity
 Diabetes mellitus, %
46.0
36.0
 < 0.001
39.9
0.11
 Admission due to HF < 1 year, %
2.0
5.2
 < 0.001
8.3
 < 0.001
 Percutaneous coronary intervention, %
10.8
15.5
0.003
16.1
0.03
 Coronary artery bypass grafting, %
4.7
6.7
0.07
9.3
0.01
 Aortic disease, %
4.8
10.8
 < 0.001
14.0
 < 0.001
Usage rate of medicine related to MBD
 Vitamin D receptor activators, %
81.3
79.6
0.40
78.2
0.29
 Calcimimetics, %
34.9
35.5
0.80
38.3
0.35
 Phosphate binders, %
84.7
78.6
 < 0.001
77.2
0.01
Blood Test
 Corrected Calcium, mg/dl
9.1 ± 0.6
9.1 ± 0.6
0.16
9.1 ± 0.7
0.55
 Phosphorus, mg/dl
5.3 ± 1.3
5.2 ± 1.2
0.76
5.2 ± 1.2
0.59
 Intact PTH, pg/ml
132 (80–193)
122 (76–185)
0.05
118 (76–162)
0.04
 Albumin, g/dl
3.6 ± 0.4
3.5 ± 0.4
 < 0.001
3.4 ± 0.37
 < 0.001
 C-reactive protein, mg/dl
0.12 (0.05–0.37)
0.12 (0.06–0.43)
0.15
0.11 (0.06–0.55)
0.15
 Hemoglobin, g/dl
11.1 ± 1.1
10.9 ± 1.2
 < 0.001
10.8 ± 1.1
0.002
Chest radiography
 Cardiothoracic ratio, %
50.2 ± 5.1
52.2 ± 5.0
 < 0.001
53.0 ± 5.0
 < 0.001
 Aortic calcification, %
57.0
70.4
 < 0.001
73.3
 < 0.001
Electrocardiogram
 Atrial fibrillation, %
5.7
9.6
0.002
12.0
0.002
 Heart rate, /min
74 ± 13
74 ± 13
0.91
75 ± 13
0.63
Transthoracic Echocardiography
 Left atrial diameter, mm
36.6 ± 6.5
38.5 ± 6.4
 < 0.001
39.1 ± 5.9
 < 0.001
 LVDd, mm
46.9 ± 6.8
46.9 ± 6.1
0.63
46.2 ± 6.4
0.26
 LVDs, mm
30.6 ± 6.4
30.5 ± 6.0
0.96
30.1 ± 6.6
0.17
 Left ventricular ejection fraction, %
63.4 ± 9.7
63.5 ± 10.0
0.52
63.5 ± 11.3
0.37
 Aortic valve calcification, %
53.3
80.7
 < 0.001
83.8
 < 0.001
 Mean pressure gradient, mmHg
5.1 ± 2.7
15.5 ± 9.6
 < 0.001
23.3 ± 11.8
 < 0.001
 Aortic valve area, cm2
2.51 ± 0.77
1.56 ± 0.62
 < 0.001
1.08 ± 0.46
 < 0.001
 Velocity max, m/s
1.43 ± 0.28
2.52 ± 0.62
 < 0.001
2.96 ± 0.87
 < 0.001
Data are presented as the mean ± standard deviation or percentages. Age, dialysis duration, intact PTH, and C-reactive protein are expressed as the median (interquartile range)
Abbreviations: Admission due to HF < 1 year, admission due to heart failure within 1 year before echocardiography; LVDd Left ventricular end-diastolic diameter, LVDs Left ventricular end-systolic diameter

Multivariate logistic regression analysis for aortic stenosis

We performed a multivariate logistic regression analysis to compare G1 and G2 with the non-AS group (Table 2). Comparison between G1 and the non-AS group showed that age, long-term dialysis, and elevated serum phosphorus levels were associated with AS (adjusted odds ratio [aOR] 1.93, 95% confidence interval [CI] 1.71–2.19, p < 0.001; aOR 1.41, 95% CI 1.21–1.64, p < 0.001; aOR 1.16, 95% CI 1.06–1.28, p = 0.001, respectively). Comparison between G2 and the non-AS group showed similar tendencies in these three variables (aOR 2.51, 95% CI 2.02–3.12, p < 0.001; aOR 1.35, 95% CI 1.06–1.71, p = 0.01; aOR 1.24, 95% CI 1.07–1.44, p = 0.005, respectively). In contrast, nephrosclerosis as a contributor to CKD was not associated with AS. Diabetes mellitus as a comorbidity was associated with AS when G1 was compared to the non-AS group (aOR 0.74, 95% CI 0.58–0.95, p = 0.02); however, no significant difference was observed between G2 and the non-AS group (aOR 0.95, 95% CI 0.64–1.40, p = 0.79).
Table 2
Adjusted odds ratio for aortic valve stenosis by multivariate logistic regression analysis
 
G1
G2
aOR (95% CI)
p value
aOR (95% CI)
p value
Male
1.02 (0.81–1.29)
0.86
0.94 (0.65–1.37)
0.75
Age (per 10 years)
1.93 (1.71–2.19)
 < 0.001
2.51 (2.02–3.12)
 < 0.001
Duration of dialysis (per 10 years)
1.41 (1.21–1.64)
 < 0.001
1.35 (1.06–1.71)
0.01
Nephrosclerosis as the primary contributor to CKD
0.94 (0.67–1.32)
0.72
0.88 (0.52–1.50)
0.65
Diabetes mellitus comorbidity
0.74 (0.58–0.95)
0.02
0.95 (0.64–1.40)
0.79
Calcimimetic use
1.16 (0.91–1.48)
0.24
1.59 (1.07–2.34)
0.02
VDRA administration
0.94 (0.70–1.25)
0.66
0.91 (0.58–1.44)
0.69
Phosphate binder use
0.87 (0.65–1.17)
0.35
0.86 (0.55–1.35)
0.52
Corrected Calcium (per 1 mg/dl)
1.27 (1.04–1.54)
0.02
1.17 (0.86–1.59)
0.31
Phosphorus (per 1 mg/dl)
1.16 (1.06–1.28)
0.001
1.24 (1.07–1.44)
0.005
Intact PTH (per 10 pg/ml)
1.00 (0.99–1.01)
0.41
1.00 (0.98–1.02)
0.91
Albumin (per 1 g/dl)
1.51 (1.05–2.17)
0.03
1.04 (0.58–1.84)
0.91
C-reactive protein (per 1 mg/dl)
0.98 (0.89–1.08)
0.67
1.02 (0.91–1.14)
0.77
Hemoglobin (per 1 g/dl)
0.85 (0.76–0.95)
0.003
0.86 (0.72–1.03)
0.10
Multivariate logistic regression analysis were perfomed to compare G1 and G2 with the non-AS group
Abbreviations: aOR adjusted Odds Ratio, CI Confidence interval, CKD Chronic kidney disease, VDRA Vitamin D receptor activator
Multivariate logistic regression analysis for aortic stenosis using ordinal categories.
The aOR for AS was determined on the basis of age, duration of dialysis, and serum phosphorus levels (Figs. 2A, 2B, and 2C). The aOR in the AS group tended to increase with an increase in the duration of dialysis. In G2, the aOR of > 15 years of dialysis was 1.86-fold greater (95% CI 1.06–3.24, p = 0.03) than that of < 5 years of dialysis. The aOR increased with an increase in serum phosphorus levels. The aORs of the serum phosphorus levels in the 5.0–5.9 and > 6.0 mg/dL groups were 1.52 and 1.83-fold higher and 2.24 and 2.66-fold higher in G1 and G2, respectively, compared to serum phosphorus levels < 4.0 mg/dL.

Characteristics of patients with aortic valve calcification

Table 3 shows the results of the multivariate logistic regression analysis for aortic valve calcification. Aortic valve calcification was associated with age, long-term dialysis, diabetes mellitus, VDRA administration, elevated serum calcium levels, and anemia but not with elevated serum phosphorus levels. The mean PG, AVA, and Vmax values were compared in patients with and without aortic valve calcification (Table 4). Significantly higher Vmax and mean PG values and significantly lower AVA values were observed in patients with aortic valve calcification.
Table 3
Adjusted odds ratio for aortic valve calcification by multivariate logistic regression analysis
 
Aortic valve calcification
OR (95% CI)
p value
Male
0.93 (0.75–1.16)
0.53
Age (per 10 years)
1.70 (1.54–1.88)
 < 0.001
Duration of dialysis (per 10 years)
1.42 (1.22–1.64)
 < 0.001
Nephrosclerosis as the primary contributor to CKD
0.88 (0.69–1.06)
0.43
Diabetes mellitus comorbidity
1.53 (1.23–1.90)
 < 0.001
Calcimimetic use
0.86 (0.69–1.06)
0.16
VDRA administration
0.70 (0.54–0.91)
0.007
Phosphate binder use
0.92 (0.69–1.23)
0.57
Corrected Calcium (per 1 mg/dl)
1.30 (1.09–1.54)
0.004
Phosphorus (per 1 mg/dl)
1.03 (0.95–1.12)
0.46
Intact PTH (per 10 pg/ml)
1.00 (0.99–1.01)
0.56
Albumin (per 1 g/dl)
1.19 (0.87–1.63)
0.28
C-reactive protein (per 1 mg/dl)
0.98 (0.90–1.07)
0.65
Hemoglobin (per 1 g/dl)
0.89 (0.81–0.98)
0.02
Table 4
Comparison of parameters with and without aortic valve calcification
 
With aortic valve calcification
Without aortic valve calcification
I value
Velocity max, m/s
1.78 ± 0.64
1.51 ± 0.50
 < 0.001
Mean pressure gradient, mmHg
8.3 ± 7.9
6.3 ± 4.8
 < 0.001
Aortic valve area, cm2
2.19 ± 0.79
2.50 ± 0.90
 < 0.001
Analyses were performed using Mann–Whitney U test

Discussion

This study showed that the prevalence of AS in patients on dialysis was as high as 20.0%, which is similar to the findings of previous reports [6, 7]. A close association between AS and aortic valve calcification was observed. Age was strongly associated with AS in patients on dialysis, as well as in the general population. Notably, hyperphosphatemia and long-term dialysis were associated with AS.
Hyperphosphatemia is seen in many patients on dialysis. Based on the United States Renal Data System statistics published in 2018, 38.1% of patients on dialysis in the USA had serum phosphorus levels ≥ 5.5 mg/dL. Based on the data published by the Japanese Society for Dialysis Therapy in 2019, 53.9% of patients on dialysis in Japan had serum phosphorus levels ≥ 5.0 mg/dL. Hyperphosphatemia promotes calcification of vascular smooth muscle cells and promotes CVD, which is associated with a high mortality in patients with CKD [2937]. Phosphorus is considered a major contributor to calcification, in both blood vessels and the aortic valve [38]. Husseini et al. reported that SLC20A1/Pit1, a phosphorus transporter associated with calcification in blood vessels, is also expressed in calcified aortic valves [39]. In two different observational studies that included approximately 100 patients who underwent dialysis, Tarrass et al. and Petrović et al. reported that phosphorus was associated with aortic valve calcification on the basis of univariate and multivariate analyses results, respectively [40, 41]. However, the association between hyperphosphatemia and AS has not been studied. In this study, an elevated serum phosphorus level was not associated with aortic valve calcification but was associated with AS. In contrast, an elevated serum calcium level was not associated with AS but was associated with aortic valve calcification. Based on these results, MBD, including hyperphosphatemia and hypercalcemia, may be associated with aortic valve calcification and AS. Interestingly, serum phosphorus levels ≥ 5.0 mg/dL (lower than the upper limit of 6.0 mg/dL established by Japanese guidelines) were associated with AS. The findings may be useful to establish target values for serum phosphorus levels.
This study showed that long-term dialysis was associated with both AS and aortic valve calcification on multivariate analysis, which included age and MBD-related factors as variables. Long-term dialysis involves various factors, such as fluid retention, chronic inflammation, and uremic toxins, that affect the cardiovascular system; therefore, it may be difficult to identify the factors that contribute to AS [4247].

Limitations

The following are the limitations of this study. (i) Patients with a history of aortic valve surgery were excluded; therefore, a serious risk factor associated with AS may have been disregarded. (ii) This study was a cross-sectional analysis; therefore, the results cannot demonstrate causality. (iii) The accuracy of TTE was unlikely to be consistent across patients in this multicenter study. Aortic valve calcification was based on the subjective interpretation of echocardiography findings by technicians at each facility. (iv) Data were not collected on whether the patients had bicuspid aortic valves, which is one of the major causes of aortic stenosis. This may have affected the results of this study. (v) The percentages of missing values for Vmax, mean PG, and AVA were 12.2%, 25.4%, and 20.9%, respectively. Although one or more of these factors were measured in all patients, missing data may potentially lead to misclassification of the AS groups. (vi) The multivariate logistic regression analysis was performed by complete cases analysis. This may have affected the results.

Conclusion

Patients who received maintenance dialysis showed a high prevalence of AS, which was associated with age, hyperphosphatemia, and duration of dialysis.

Acknowledgements

The authors acknowledge the support provided by Futoshi Suzuki (Fujita Health University), Noriko Suzuki (Fujita Health University), and the members of this cohort study. The Aichi Kidney Foundation and Japanese Association of Dialysis Physicians funded this study.

Declarations

This study was performed according to the Ethics of Clinical Research (the Helsinki Declaration). This study was approved by Fujita Health University Center for Clinical Trial and Research Support (approval number: HM16–373). All participants involved in this study were gave informed consent after explanation of the purpose of the study and agreed to participate. This study was registered in the clinical trial registry (UMIN 000026756) on April 1, 2017.
Not applicable.

Competing interests

D. Inaguma received lecture fees from Ono Pharmaceutical Co., Ltd. and Kyowa Kirin Co., Ltd. Y. Yuzawa received research support grants from Otsuka Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., and Chugai Pharmaceutical Co., Ltd. The other authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Anhänge

Supplementary Information

Literatur
1.
Zurück zum Zitat Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.PubMedCrossRef Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.PubMedCrossRef
2.
Zurück zum Zitat Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, Chambless LE, Coresh J. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol. 2007;18(4):1307–15.PubMedCrossRef Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, Chambless LE, Coresh J. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol. 2007;18(4):1307–15.PubMedCrossRef
3.
Zurück zum Zitat Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351(13):1285–95.PubMedCrossRef Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351(13):1285–95.PubMedCrossRef
4.
Zurück zum Zitat Wanner C, Amann K, Shoji T. The heart and vascular system in dialysis. Lancet. 2016;388(10041):276–84.PubMedCrossRef Wanner C, Amann K, Shoji T. The heart and vascular system in dialysis. Lancet. 2016;388(10041):276–84.PubMedCrossRef
5.
Zurück zum Zitat Cabrera CS, Lee AS, Olsson M, Schnecke V, Westman K, Lind M, Greasley PJ, Skrtic S. Impact of CKD progression on cardiovascular disease risk in a contemporary UK cohort of individuals with diabetes. Kidney Int Rep. 2020;5(10):1651–60.PubMedPubMedCentralCrossRef Cabrera CS, Lee AS, Olsson M, Schnecke V, Westman K, Lind M, Greasley PJ, Skrtic S. Impact of CKD progression on cardiovascular disease risk in a contemporary UK cohort of individuals with diabetes. Kidney Int Rep. 2020;5(10):1651–60.PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Straumann E, Meyer B, Misteli M, Blumberg A, Jenzer HR. Aortic and mitral valve disease in patients with end stage renal failure on long-term haemodialysis. Br Heart J. 1992;67(3):236–9.PubMedPubMedCentralCrossRef Straumann E, Meyer B, Misteli M, Blumberg A, Jenzer HR. Aortic and mitral valve disease in patients with end stage renal failure on long-term haemodialysis. Br Heart J. 1992;67(3):236–9.PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Schönenberger A, Winkelspecht B, Köhler H, Girndt M. High prevalence of aortic valve alterations in haemodialysis patients is associated with signs of chronic inflammation. Nephron Clin Pract. 2004;96(2):c48-55.PubMedCrossRef Schönenberger A, Winkelspecht B, Köhler H, Girndt M. High prevalence of aortic valve alterations in haemodialysis patients is associated with signs of chronic inflammation. Nephron Clin Pract. 2004;96(2):c48-55.PubMedCrossRef
8.
Zurück zum Zitat Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med. 1999;341(3):142–7.PubMedCrossRef Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med. 1999;341(3):142–7.PubMedCrossRef
9.
Zurück zum Zitat Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM. Clinical factors associated with calcific aortic valve disease. cardiovascular health study. J Am Coll Cardiol. 1997;29(3):630–4.PubMedCrossRef Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM. Clinical factors associated with calcific aortic valve disease. cardiovascular health study. J Am Coll Cardiol. 1997;29(3):630–4.PubMedCrossRef
10.
Zurück zum Zitat Perkovic V, Hunt D, Griffin SV, du Plessis M, Becker GJ. Accelerated progression of calcific aortic stenosis in dialysis patients. Nephron Clin Pract. 2003;94(2):c40–5.PubMedCrossRef Perkovic V, Hunt D, Griffin SV, du Plessis M, Becker GJ. Accelerated progression of calcific aortic stenosis in dialysis patients. Nephron Clin Pract. 2003;94(2):c40–5.PubMedCrossRef
11.
Zurück zum Zitat Ohara T, Hashimoto Y, Matsumura A, Suzuki M, Isobe M. Accelerated progression and morbidity in patients with aortic stenosis on chronic dialysis. Circ J. 2005;69(12):1535–9.PubMedCrossRef Ohara T, Hashimoto Y, Matsumura A, Suzuki M, Isobe M. Accelerated progression and morbidity in patients with aortic stenosis on chronic dialysis. Circ J. 2005;69(12):1535–9.PubMedCrossRef
12.
Zurück zum Zitat Samad Z, Sivak JA, Phelan M, Schulte PJ, Patel U, Velazquez EJ. Prevalence and outcomes of left-sided valvular heart disease associated with chronic kidney disease. J Am Heart Assoc. 2017;6(10):e006044.PubMedPubMedCentralCrossRef Samad Z, Sivak JA, Phelan M, Schulte PJ, Patel U, Velazquez EJ. Prevalence and outcomes of left-sided valvular heart disease associated with chronic kidney disease. J Am Heart Assoc. 2017;6(10):e006044.PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Zentner D, Hunt D, Chan W, Barzi F, Grigg L, Perkovic V. Prospective evaluation of aortic stenosis in end-stage kidney disease: a more fulminant process? Nephrol Dial Transplant. 2011;26(5):1651–5.PubMedCrossRef Zentner D, Hunt D, Chan W, Barzi F, Grigg L, Perkovic V. Prospective evaluation of aortic stenosis in end-stage kidney disease: a more fulminant process? Nephrol Dial Transplant. 2011;26(5):1651–5.PubMedCrossRef
14.
Zurück zum Zitat Lindroos M, Kupari M, Heikkilä J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol. 1993;21(5):1220–5.PubMedCrossRef Lindroos M, Kupari M, Heikkilä J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol. 1993;21(5):1220–5.PubMedCrossRef
15.
Zurück zum Zitat Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Bärwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A. A prospective survey of patients with valvular heart disease in Europe: the euro heart survey on valvular heart disease. Eur Heart J. 2003;24(13):1231–43.PubMedCrossRef Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Bärwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A. A prospective survey of patients with valvular heart disease in Europe: the euro heart survey on valvular heart disease. Eur Heart J. 2003;24(13):1231–43.PubMedCrossRef
16.
Zurück zum Zitat Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis: a disease of the valve and the myocardium. J Am Coll Cardiol. 2012;60(19):1854–63.PubMedCrossRef Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis: a disease of the valve and the myocardium. J Am Coll Cardiol. 2012;60(19):1854–63.PubMedCrossRef
17.
Zurück zum Zitat Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD, Simmons CA, Masters KS, Mathieu P, O’Brien KD, Schoen FJ, Towler DA, Yoganathan AP, Otto CM. Calcific aortic valve disease: not simply a degenerative process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update. Circulation. 2011;124(16):1783–91.PubMedPubMedCentralCrossRef Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD, Simmons CA, Masters KS, Mathieu P, O’Brien KD, Schoen FJ, Towler DA, Yoganathan AP, Otto CM. Calcific aortic valve disease: not simply a degenerative process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update. Circulation. 2011;124(16):1783–91.PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Rabkin SW. The association of hypertension and aortic valve sclerosis. Blood Press. 2005;14(5):264–72.PubMedCrossRef Rabkin SW. The association of hypertension and aortic valve sclerosis. Blood Press. 2005;14(5):264–72.PubMedCrossRef
19.
Zurück zum Zitat Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA, Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352(23):2389–97.PubMedCrossRef Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA, Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352(23):2389–97.PubMedCrossRef
20.
Zurück zum Zitat Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R, SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343–56.PubMedCrossRef Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R, SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343–56.PubMedCrossRef
21.
Zurück zum Zitat Novaro GM, Katz R, Aviles RJ, Gottdiener JS, Cushman M, Psaty BM, Otto CM, Griffin BP. Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the cardiovascular health study. J Am Coll Cardiol. 2007;50(20):1992–8.PubMedCrossRef Novaro GM, Katz R, Aviles RJ, Gottdiener JS, Cushman M, Psaty BM, Otto CM, Griffin BP. Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the cardiovascular health study. J Am Coll Cardiol. 2007;50(20):1992–8.PubMedCrossRef
22.
Zurück zum Zitat Bansal N, McCulloch CE, Lin F, Robinson-Cohen C, Rahman M, Kusek JW, Anderson AH, Xie D, Townsend RR, Lora CM, Wright J, Go AS, Ojo A, Alper A, Lustigova E, Cuevas M, Kallem R, Hsu CY, CRIC Study Investigators. Different components of blood pressure are associated with increased risk of atherosclerotic cardiovascular disease versus heart failure in advanced chronic kidney disease. Kidney Int. 2016;90(6):1348–56.PubMedPubMedCentralCrossRef Bansal N, McCulloch CE, Lin F, Robinson-Cohen C, Rahman M, Kusek JW, Anderson AH, Xie D, Townsend RR, Lora CM, Wright J, Go AS, Ojo A, Alper A, Lustigova E, Cuevas M, Kallem R, Hsu CY, CRIC Study Investigators. Different components of blood pressure are associated with increased risk of atherosclerotic cardiovascular disease versus heart failure in advanced chronic kidney disease. Kidney Int. 2016;90(6):1348–56.PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, Cushman WC, Hawfield AT, Johnson KC, Lewis CE, Oparil S, Rocco MV, Sink KM, Whelton PK, Wright JT Jr, Basile J, Beddhu S, Bhatt U, Chang TI, Chertow GM, Chonchol M, Freedman BI, Haley W, Ix JH, Katz LA, Killeen AA, Papademetriou V, Ricardo AC, Servilla K, Wall B, Wolfgram D, Yee J, SPRINT Research Group. Effects of Intensive BP control in CKD. J Am Soc Nephrol. 2017;28(9):2812–23.PubMedPubMedCentralCrossRef Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, Cushman WC, Hawfield AT, Johnson KC, Lewis CE, Oparil S, Rocco MV, Sink KM, Whelton PK, Wright JT Jr, Basile J, Beddhu S, Bhatt U, Chang TI, Chertow GM, Chonchol M, Freedman BI, Haley W, Ix JH, Katz LA, Killeen AA, Papademetriou V, Ricardo AC, Servilla K, Wall B, Wolfgram D, Yee J, SPRINT Research Group. Effects of Intensive BP control in CKD. J Am Soc Nephrol. 2017;28(9):2812–23.PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–34.PubMedCrossRef Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–34.PubMedCrossRef
25.
Zurück zum Zitat Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, James MT, Hemmelgarn BR, Alberta Kidney Disease Network. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380(9844):807–14.PubMedCrossRef Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, James MT, Hemmelgarn BR, Alberta Kidney Disease Network. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380(9844):807–14.PubMedCrossRef
26.
Zurück zum Zitat Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225–32.PubMedCrossRef Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225–32.PubMedCrossRef
27.
Zurück zum Zitat Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16(2):520–8.PubMedCrossRef Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16(2):520–8.PubMedCrossRef
28.
Zurück zum Zitat Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52(3):519–30.PubMedCrossRef Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52(3):519–30.PubMedCrossRef
29.
Zurück zum Zitat Giachelli CM, Speer MY, Li X, Rajachar RM, Yang H. Regulation of vascular calcification: roles of phosphate and osteopontin. Circ Res. 2005;96(7):717–22.PubMedCrossRef Giachelli CM, Speer MY, Li X, Rajachar RM, Yang H. Regulation of vascular calcification: roles of phosphate and osteopontin. Circ Res. 2005;96(7):717–22.PubMedCrossRef
30.
Zurück zum Zitat Shroff R, Long DA, Shanahan C. Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol. 2013;24(2):179–89.PubMedCrossRef Shroff R, Long DA, Shanahan C. Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol. 2013;24(2):179–89.PubMedCrossRef
31.
Zurück zum Zitat Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342(20):1478–83.PubMedCrossRef Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342(20):1478–83.PubMedCrossRef
32.
Zurück zum Zitat Isaka Y, Hamano T, Fujii H, Tsujimoto Y, Koiwa F, Sakaguchi Y, Tanaka R, Tomiyama N, Tatsugami F, Teramukai S. Optimal phosphate control related to coronary artery calcification in dialysis patients. J Am Soc Nephrol. 2021;32(3):723–35.PubMedPubMedCentralCrossRef Isaka Y, Hamano T, Fujii H, Tsujimoto Y, Koiwa F, Sakaguchi Y, Tanaka R, Tomiyama N, Tatsugami F, Teramukai S. Optimal phosphate control related to coronary artery calcification in dialysis patients. J Am Soc Nephrol. 2021;32(3):723–35.PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–18.PubMedCrossRef Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–18.PubMedCrossRef
34.
Zurück zum Zitat Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, Kronenberg F, Marcelli D, Passlick-Deetjen J, Schernthaner G, Fouqueray B, Wheeler DC, ARO Investigators. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant. 2011;26(6):1948–55.PubMedCrossRef Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, Kronenberg F, Marcelli D, Passlick-Deetjen J, Schernthaner G, Fouqueray B, Wheeler DC, ARO Investigators. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant. 2011;26(6):1948–55.PubMedCrossRef
35.
Zurück zum Zitat Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12(10):2131–8.PubMedCrossRef Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12(10):2131–8.PubMedCrossRef
36.
Zurück zum Zitat Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK. Predictors and consequences of altered mineral metabolism: the dialysis outcomes and practice patterns study. Kidney Int. 2005;67(3):1179–87.PubMedCrossRef Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK. Predictors and consequences of altered mineral metabolism: the dialysis outcomes and practice patterns study. Kidney Int. 2005;67(3):1179–87.PubMedCrossRef
37.
Zurück zum Zitat Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005;16(6):1788–93.PubMedCrossRef Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005;16(6):1788–93.PubMedCrossRef
38.
Zurück zum Zitat Rattazzi M, Bertacco E, Del Vecchio A, Puato M, Faggin E, Pauletto P. Aortic valve calcification in chronic kidney disease. Nephrol Dial Transplant. 2013;28(12):2968–76.PubMedCrossRef Rattazzi M, Bertacco E, Del Vecchio A, Puato M, Faggin E, Pauletto P. Aortic valve calcification in chronic kidney disease. Nephrol Dial Transplant. 2013;28(12):2968–76.PubMedCrossRef
39.
Zurück zum Zitat El Husseini D, Boulanger MC, Fournier D, Mahmut A, Bossé Y, Pibarot P, Mathieu P. High expression of the Pi-transporter SLC20A1/Pit1 in calcific aortic valve disease promotes mineralization through regulation of Akt-1. PLoS One. 2013;8(1):e53393.PubMedPubMedCentralCrossRef El Husseini D, Boulanger MC, Fournier D, Mahmut A, Bossé Y, Pibarot P, Mathieu P. High expression of the Pi-transporter SLC20A1/Pit1 in calcific aortic valve disease promotes mineralization through regulation of Akt-1. PLoS One. 2013;8(1):e53393.PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Tarrass F, Benjelloun M, Zamd M, Medkouri G, Hachim K, Benghanem MG, Ramdani B. Heart valve calcifications in patients with end-stage renal disease: analysis for risk factors. Nephrology (Carlton). 2006;11(6):494–6.CrossRef Tarrass F, Benjelloun M, Zamd M, Medkouri G, Hachim K, Benghanem MG, Ramdani B. Heart valve calcifications in patients with end-stage renal disease: analysis for risk factors. Nephrology (Carlton). 2006;11(6):494–6.CrossRef
41.
Zurück zum Zitat Petrović D, Obrenović R, Stojimirović B. Risk factors for aortic valve calcification in patients on regular hemodialysis. Int J Artif Organs. 2009;32(3):173–9.PubMedCrossRef Petrović D, Obrenović R, Stojimirović B. Risk factors for aortic valve calcification in patients on regular hemodialysis. Int J Artif Organs. 2009;32(3):173–9.PubMedCrossRef
42.
Zurück zum Zitat Kalantar-Zadeh K, Regidor DL, Kovesdy CP, Van Wyck D, Bunnapradist S, Horwich TB, Fonarow GC. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation. 2009;119(5):671–9.PubMedPubMedCentralCrossRef Kalantar-Zadeh K, Regidor DL, Kovesdy CP, Van Wyck D, Bunnapradist S, Horwich TB, Fonarow GC. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation. 2009;119(5):671–9.PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Cozzolino M, Mangano M, Stucchi A, Ciceri P, Conte F, Galassi A. Cardiovascular disease in dialysis patients. Nephrol Dial Transplant. 2018;33(suppl_3):iii28–34.PubMedPubMedCentralCrossRef Cozzolino M, Mangano M, Stucchi A, Ciceri P, Conte F, Galassi A. Cardiovascular disease in dialysis patients. Nephrol Dial Transplant. 2018;33(suppl_3):iii28–34.PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat Sun J, Axelsson J, Machowska A, Heimbürger O, Bárány P, Lindholm B, Lindström K, Stenvinkel P, Qureshi AR. Biomarkers of cardiovascular disease and mortality risk in patients with advanced CKD. Clin J Am Soc Nephrol. 2016;11(7):1163–72.PubMedPubMedCentralCrossRef Sun J, Axelsson J, Machowska A, Heimbürger O, Bárány P, Lindholm B, Lindström K, Stenvinkel P, Qureshi AR. Biomarkers of cardiovascular disease and mortality risk in patients with advanced CKD. Clin J Am Soc Nephrol. 2016;11(7):1163–72.PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Liabeuf S, Lenglet A, Desjardins L, Neirynck N, Glorieux G, Lemke HD, Vanholder R, Diouf M, Choukroun G, Massy ZA, European Uremic Toxin Work Group (EUTox). Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney Int. 2012;82(12):1297–303.PubMedCrossRef Liabeuf S, Lenglet A, Desjardins L, Neirynck N, Glorieux G, Lemke HD, Vanholder R, Diouf M, Choukroun G, Massy ZA, European Uremic Toxin Work Group (EUTox). Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney Int. 2012;82(12):1297–303.PubMedCrossRef
46.
Zurück zum Zitat Stubbs JR, House JA, Ocque AJ, Zhang S, Johnson C, Kimber C, Schmidt K, Gupta A, Wetmore JB, Nolin TD, Spertus JA, Yu AS. Serum Trimethylamine-N-Oxide is elevated in CKD and correlates with coronary atherosclerosis burden. J Am Soc Nephrol. 2016;27(1):305–13.PubMedCrossRef Stubbs JR, House JA, Ocque AJ, Zhang S, Johnson C, Kimber C, Schmidt K, Gupta A, Wetmore JB, Nolin TD, Spertus JA, Yu AS. Serum Trimethylamine-N-Oxide is elevated in CKD and correlates with coronary atherosclerosis burden. J Am Soc Nephrol. 2016;27(1):305–13.PubMedCrossRef
47.
Zurück zum Zitat Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, Choukroun G, Vanholder R, Massy ZA, European Uremic Toxin Work Group (EUTox). Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009;4(10):1551–8.PubMedPubMedCentralCrossRef Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, Choukroun G, Vanholder R, Massy ZA, European Uremic Toxin Work Group (EUTox). Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009;4(10):1551–8.PubMedPubMedCentralCrossRef
Metadaten
Titel
Factors associated with aortic valve stenosis in Japanese patients with end-stage kidney disease
verfasst von
Yuji Sasakawa
Naoki Okamoto
Maya Fujii
Jyoichiro Kato
Yukio Yuzawa
Daijo Inaguma
Publikationsdatum
01.12.2022
Verlag
BioMed Central
Erschienen in
BMC Nephrology / Ausgabe 1/2022
Elektronische ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-022-02758-y

Weitere Artikel der Ausgabe 1/2022

BMC Nephrology 1/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.